Skip to main content
. Author manuscript; available in PMC: 2019 Aug 11.
Published in final edited form as: Oncogene. 2019 Feb 11;38(22):4412–4424. doi: 10.1038/s41388-019-0712-y

Figure 5. ‘Acquired pluripotent pathways drive castration resistant prostate cancer independent of conventional AR signalling’.

Figure 5

(A) Diagram illustrating the exons of the androgen receptor (AR) and variants (AR-Vs) that siEX1, siEX7 and siCE3 target. NTD, N-terminal domain; DBD, DNA-binding domain; LBD, ligand-binding domain; CE, Cryptic exon.

(B) Expression of AR was measured by qPCR following knockdown of AR-FL (siEX7), AR-V7 (siCE3) and all AR (siEX1) in CWR22Rv1 cells cultured in FM, SDM and APSCE. Data is represented as fold change of siCTRL experimental arm. Data represents at least three independent experiments ± SEM.

(C) Same as in (B) but measurement of AR-V7 expression.

(D) Same as in (C) but measurement of PSA expression. (*denotes p-value < 0.05).

(E) Same as in (C) but measurement of KLK2 expression.